Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

Abstract: Kessler Project is a pacifier that can be filled with distilled water or the like and then be refrigerated or frozen. The preferred embodiment of the invention utilizes a mouth guard, a nipple, a ring, a cap, and a base. To use the preferred embodiment of Kessler Project, an individual would remove the cap on the base and fill the nipple and base of the device with water. The cap would then snap onto the base of the device, allowing the user to place the device into a refrigerator or freezer to cool. Once the appropriate water temperature is reached, the device is removed from the refrigerator or freezer and given to the infant. The ring of the device is dimensioned to be easy for an infant to grasp to allow him to place the nipple into his mouth. The mouth guard prevents the device from being swallowed when the nipple is inserted into the baby's mouth. The design of the device allows the baby to place the nipple in his mouth without having to constantly hold the cold ring of the device.

Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.